… of Bristol Myers Squibb’s Abraxane® in the United States. Cipla … is a therapeutic equivalent to Abraxane®, a widely used chemotherapy drug … for the treatment of metastatic breast cancer, locally advanced or metastatic non …

… receptor–positive metastatic breast cancers that express HER2,” … capecitabine, nab-paclitaxel (Abraxane), or paclitaxel. PFS … of patients with metastatic breast cancer,” Dave Fredrickson, … HER2-ultralow metastatic breast cancer following disease progression …

… Bristol Myers Squibb's Abraxane for injectable suspension 100 mg … for the treatment of metastatic breast cancer, locally advanced or metastatic non …

… during taxane-based chemotherapy for breast cancer are less likely to develop … among women undergoing chemo for breast cancer. (Results from this trial were … using paclitaxel or nab-paclitaxel (Abraxane) before or after surgery. The …

… professor of medicine and breast cancer specialist, Division of … in patients with breast cancer. Although the breast cancer treatment paradigm … m2), or nab-paclitaxel (Abraxane) weekly or every 3 … clinical diagnosis of metastatic breast cancer. Patients on the …

… breast cancer, and Komen Distinguished Chair in Clinical Breast Cancer … of cisplatin/Abraxane/pembrolizumab followed … breast cancer. Presented at: 2024 San Antonio Breast Cancer … breast cancer (TNBC). Presented at: 2024 San Antonio Breast Cancer …

… low or HER2-ultralow metastatic breast cancer following endocrine therapy,” Ken … comprising capecitabine, nab-paclitaxel (Abraxane), or paclitaxel. Key stratification … or HER2-ultralow metastatic breast cancer following disease progression after …

… The rising incidence of metastatic breast cancer, particularly among younger populations, … comprising capecitabine, nab-paclitaxel (Abraxane), or paclitaxel. Stratification factors … with HER2-ultralow metastatic breast cancer eligible for Enhertu. News …

… targeted therapy for metastatic breast cancer. Alternatively, they could … 59.8%), nab-paclitaxel (Abraxane; 24.4%), or paclitaxel … HER2-ultralow metastatic breast cancer following disease progression … or HER2-ultralow metastatic breast cancer (mBC) with prior …

… receptor 2-negative (HER2–) breast cancer (BC), with outcomes … cycles of nab-paclitaxel (Abraxane; Abraxis BioScience) and carboplatin … clinical trial of breast cancer neo-adjuvant therapy based … HR+/HER2- breast cancer-FINEST study. Cancer Communications …